An interventional study of Continuous sedentary reduction intervention and Bouted sedentary reduction intervention in Sedentary Time and Frailty, sponsored by Johns Hopkins Bloomberg School of Public Health. Active, not recruiting at 2 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Johns Hopkins Bloomberg School of Public Health · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 452 studies in Sedentary Behavior with a site in United States — 61 open to participants now, 89 under way, none of them phase 3. Sedentary Behavior · United States.
Among the 452 studies in Sedentary Behavior with a site in United States, this one is the 192nd largest by enrollment of the 421 interventional ones that give a count, is one of 45 that started in 2023, is one of 386 with no phase, reaches primary completion later than 18 of the 88 other live ones, and was the 364th registered.
1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.
Browse Sedentary Behavior studies →61 of the 452 studies in Sedentary Behavior with a site in United States are open now. Recruiting first, the newest first:
St. Louis University · Sites in United States
Ages 18–69
University of Pittsburgh · Sites in United States
Ages 14–26
University of Wisconsin, River Falls · Sites in United States
Ages 18–60 · Healthy volunteers
The University of Tennessee, Knoxville · Sites in United States
Ages 65+
San Diego State University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
452 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 15 · Phase 3 3 · Phase 4 2
First in 2000; this study’s year is marked. 45 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is close to the median of 60 across 1,077 interventional studies indexed under Sedentary Behavior.
Median enrollment 60 across the 421 interventional studies, 122 across the 30 observational. Of the 335 that completed or were terminated, 105 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 452 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins Bloomberg School of Public Health is the lead sponsor of 371 studies on the registry; 41 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Johns Hopkins Bloomberg School of Public Health has 1 study filed under Sedentary Behavior — fewer than ten, so there is no comparison to draw.
40 of the studies in Sedentary Behavior with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07520786University of GeorgiaChanges in 24-hour Activity Cycle Behaviors During a Time-Restricted Eating Intervention in College-Aged Women | 2026-11 |
| NCT06923397Dana-Farber Cancer InstituteInterrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial | 2026-11-28 |
| NCT06116435University of Colorado, DenverA Pilot Factorial Trial of an Integrated Lifestyle Intervention | 2026-12 |
| NCT06754280University of Illinois at ChicagoAn Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease | 2026-12 |
| NCT07270016University of PittsburghPilot-Testing Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes | 2026-12 |
Add all 40 to your calendar (.ics) → With an account.
Among the 452 studies in Sedentary Behavior with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this behavioral clinical trial is to compare two different ways of becoming less sedentary and more active in 60 older adults at elevated risk of becoming frail.
The main question this project aims to answer are whether participants in each intervention are able to gradually replace 30 minutes of sedentary (sitting-like) behavior with very light walking over 60 days.
There are other questions this project aims to answer that include:
Participants will be randomized into one of two sedentary reduction behavior programs; one program that gradually replaces sedentary time with one 30-minute walking bout and the other program that gradually replaces sedentary time with three 10-minute walking bouts in the morning, afternoon, and evening. Researchers will compare both programs to see which one is easier to achieve and maintain over 60 days.
Initiating and maintaining habitual physical activity is difficult for sedentary older adults, particularly those encumbered by health challenges. The 2018 US Physical Activity Guidelines recommends that all adults perform ≥150 minutes/week of physical activity and reduce sedentary behaviors. Yet, traditional approaches to increase physical activity do little to address sedentary behavior reduction, especially for older adults. Lower sedentary behavior is associated with improved biological and psychosocial health-independent of meeting physical activity guidelines. Thus, there remains a critical need to implement and evaluate a structured way to reduce sedentary behavior as a potential pathway for habitual physical activity engagement.
This project aims to test two prescribe-able and feasible strategies to initiate and incorporate sedentary behavior reduction into daily lifestyle with remote monitoring. The interventions are an inexpensive and low burden approach to reduce sedentary behavior and promote habitual physical activity. Moreover, accelerometer-based outcomes of sedentary behavior are novel in intervention settings, particularly when measured in free-living, real-world settings. Lastly, this project directly addresses a gap of successful remotely deployable interventions geared to initiate and build activity into daily life by replacing sedentary time among older adults.
Aim 1. Explore the effectiveness of 2 interventions to reduce sedentary time in pre-frail older adults over 2 months
Hypothesis 1a. Each intervention will reduce objectively measured daily sedentary time from baseline levels over 2 months.
Hypothesis 1b. The continuous intervention will result in more reduction of objectively measured sedentary time than the bouts intervention.
Aim 2. Explore the dose-response relationship between sedentary time changes and patient-reported outcomes that include fatigue, fatigability, anxiety, general and exercise-based self-efficacy, stress, pain, and mood over 2 months
Hypothesis 2: Decreased daily sedentary time over 2 months is associated with decreased fatigue, fatigability, anxiety, stress, and pain, and increased general and exercise-based self-efficacy and mood over 2 months.
Aim 3. Explore the dose-response relationship between sedentary time changes and biomarkers of frailty-related inflammation, including serum interleukin (IL-6) (pg/mL) and tumor necrosis factor (TNF) -alpha receptor 1 (pg/mL) over 2 months
Hypothesis 3. Decreased daily sedentary time is associated with decreased serum (IL-6) and TNF-alpha receptor 1 over 2 months.
Aim 4. Explore the dose-response relationship between changes in sedentary time with biomarkers of glucose and lipid metabolism (glucose, insulin, total cholesterol (TC), low-density lipoprotein cholesterol (LDLC), triglycerides, high-density lipoprotein cholesterol (HDLC)), a cytokine marker related to frailty (Growth/Differentiation Factor-15; (GDF-15), hemoglobin A1C (hbA1c), non-esterified free fatty acid, and untargeted metabolomics-based markers of energy regulation.
Hypothesis 4. Decreased daily sedentary time is associated with decreased levels of blood glucose, insulin, TC, LDLC, triglycerides and increased HDLC, decreased GDF-15, decreased hbA1c, decreased non-esterified free fatty acid, and lower circulating metabolites necessary for energy regulation over 2 months.
Aim 5. Explore the dose-response and diurnal relationships between changes in sedentary time and interstitial glucose continuously monitored over 24 hours for 14 consecutive days using a Libre Pro sensor at baseline and 2 months later
Hypothesis 5. Decreased sedentary time is associated with decreased overall glucose and different time-of-day glucose levels, coefficient of variation, % of time in glucose at various ranges (e.g., ≥200, ≥180, ≥140, 70-180, 70-140, \<70, \<54 mg/dL), mean daily difference, and mean amplitude of glycemic excursion) over 2 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Structured intervention to progressively replace sedentary time with one daily 30-minute light-intensity walking bout
Behavioral: Continuous sedentary reduction intervention
Structured intervention to progressively replace sedentary time with three daily 10-minute light-intensity walking bouts
Behavioral: Bouted sedentary reduction intervention
During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts). During Phase 2, the three 10-minute walking bouts will be gradually combined into one 30-minute bout over the course of 20 days.
During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts). During Phase 2, the three 10-minute walking bouts will be maintained over the course of 20 days.
Change in Sedentary Time
Sedentary time measured with a wrist worn monitor containing an accelerometer sensor This measurement is collected under a 7-day/24-hour wear protocol at baseline and again 2 months afterwards to determine the change in sedentary time before and after either intervention.
Time frame: Baseline, 2 months
Intervention Difference in the Change in Sedentary Time
Comparing the 2-month change in sedentary time between the two interventions
Time frame: Baseline, 2 months
Change in Physical Activity Accumulation
Physical activity fragmentation (e.g., broken up activity accumulation) wrist worn monitor containing an accelerometer sensor
Time frame: Baseline, 2 months
Change in Walking Ability
Ability to walk measured at a usual walking pace for 400m at baseline and 2 months afterwards.
Time frame: Baseline, 2 months
Change in Walking Speed
Walking speed measured at a usual walking pace for 4m at baseline and 2 months afterwards.
Time frame: Baseline, 2 months
Change in Fatigue
Fatigue measured using a Fatigue Scale questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-13 where higher scores mean higher fatigue.
Time frame: Baseline, 2 months
Change in Fatigability
Fatigability measured using a Pittsburgh Fatigability questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-100 where higher scores mean higher fatigability.
Time frame: Baseline, 2 months
Change in Anxiety
Anxiety measured using an Anxiety Scale questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-20 where higher scores mean higher anxiety.
Time frame: Baseline, 2 months
Change in General Self Efficacy
General Self Efficacy measured using a General Self Efficacy questionnaire measured at baseline and 2 months afterwards On the questionnaire, a score can range from 0-50 where higher scores mean higher general self efficacy.
Time frame: Baseline, 2 months
Change in Exercise-based Self Efficacy
Exercise-based Self Efficacy measured using an Exercise-based Self Efficacy questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-90 where higher scores mean higher exercise-based self efficacy.
Time frame: Baseline, 2 months
Change in Stress
Stress measured using a Perceived Stress Scale questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-70 where higher scores mean higher stress.
Time frame: Baseline, 2 months
Change in Pain
Pain measured using a modified version of the McGill pain questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-5 where higher scores mean greater pain.
Time frame: Baseline, 2 months
Change in Mood
Mood measured using a Profile of Mood Status questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-20 where higher scores mean greater mood disturbance.
Time frame: Baseline, 2 months
Change in Inflammation
Inflammation measured from blood draws quantifying serum IL-6 (pg/mL) and TNF-alpha receptor 1 (pg/mL) at baseline and 2 months afterwards
Time frame: Baseline, 2 months
Change in Blood Glucose
Blood glucose measured from blood draws
Time frame: Baseline, 2 months
Change in Insulin
Insulin measured from blood draws
Time frame: Baseline, 2 months
Change in Total Cholesterol
Total cholesterol measured from blood draws
Time frame: Baseline, 2 months
Change in Low-Density Lipoprotein Cholesterol
Low-density lipoprotein cholesterol measured from blood draws
Time frame: Baseline, 2 months
Change in High-Density Lipoprotein Cholesterol
High-density lipoprotein cholesterol measured from blood draws
Time frame: Baseline, 2 months
Change in Triglycerides
Triglycerides measured from blood draws
Time frame: Baseline, 2 months
Change in Growth/Differentiation Factor-15
Growth/Differentiation Factor-15 measured from blood draws
Time frame: Baseline, 2 months
Change in Metabolites
Untargeted metabolomics-based markers of energy regulation measured from blood draws
Time frame: Baseline, 2 months
Change in Hemoglobin A1c
Hemoglobin A1c measured from blood draws
Time frame: Baseline, 2 months
Change in Non-Esterified Free Fatty Acid
Non-Esterified Free Fatty Acid measured from blood draws
Time frame: Baseline, 2 months
Change in Interstitial Glucose
Interstitial glucose measured using a continuous glucose monitor worn 24-hours each day for 14 consecutive days at baseline and 2 months afterwards. Specific measurements include overall glucose and different time-of-day glucose levels, coefficient of variation, % of time in glucose at various ranges (e.g., ≥200, ≥180, ≥140, 70-180, 70-140, \<70, \<54 mg/dL), mean daily difference, and mean amplitude of glycemic excursion).
Time frame: Baseline, 2 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2023 to primary completion in Jul 2026, 31 months.
Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's 31 months is above that.
Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.
Primary completion moved twice since we started tracking on Sep 25, 2026: Nov 2025 → Jul 2026, last on Oct 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins Bloomberg School of Public Health →